Pain News and Research

Latest Pain News and Research

Epiphany Biosciences announces results from its valomaciclovir Phase 2b trial for shingles

Epiphany Biosciences announced results from its Phase 2b dose-ranging study of EPB-348 (valomaciclovir) in patients with shingles (herpes zoster) infection. The study's primary endpoint was non-inferiority of once-daily valomaciclovir compared to thrice-daily valacyclovir in terms of time to complete crusting of the shingles rash.

18 Nov 2009

Recent data from CNSBio's Phase IIa CNSB015 trial to be presented at the Neuropathic Pain conference

CNSBio Inc. will present recent Phase IIa proof-of-concept clinical trial data for CNSB015, an orally administered potassium channel modulator used in combination with opioids for the treatment of neuropathic pain, at the 12th International Conference on the Mechanisms and Treatment of Neuropathic Pain on November 20-21, 2009 in San Francisco, CA.

18 Nov 2009

Clinical Data commences patient enrollment in Stedivaze Phase III trial

Clinical Data, Inc. today announced that it has enrolled the first patient in its initial Phase III trial of Stedivaze™, a potential best-in-class vasodilator for use in cardiac stress testing. The study will evaluate the safety and efficacy of Stedivaze (apadenoson) for use as a pharmacologic stress agent in myocardial perfusion imaging (MPI), a method for detecting defects in the blood supply to the heart.

18 Nov 2009

SynCon Chikungunya virus DNA vaccine induces protective neutralizing antibody responses in animal model

Inovio Biomedical Corporation, a leader in DNA vaccine design, development and delivery, announced today that the company's SynCon™ Chikungunya virus DNA vaccine induced protective neutralizing antibody responses in a preclinical non-human primate model.

18 Nov 2009

New source of information can help prescribers and patients in understanding anticipated side effects of treatments

In clinical trials for cancer, it is standard for clinicians rather than patients to report adverse symptom side effects from treatments, such as nausea and fatigue. At present, patient self-reporting, although important, is not a well studied source of this information.

18 Nov 2009

Pluristem’s PLX-PAD holds promise for critical limb ischemia

Pluristem Therapeutics Inc. today announced that safety and potential efficacy parameters were demonstrated by the three month follow up data from the first patient ever to receive its placenta derived cell therapy product, PLX-PAD. The patient is participating in a Phase I dose-escalating clinical trial in Europe with PLX-PAD, the company’s leading product candidate for the treatment of critical limb ischemia (CLI), the end-stage of peripheral artery disease (PAD).

18 Nov 2009

Drug interaction between clopidogrel and omeprazole: New safety information

Today the FDA notified healthcare professionals of new safety information concerning a drug interaction between clopidogrel, an anti-clotting medication, and omeprazole, a proton pump inhibitor (PPI) used to reduce stomach acid.

18 Nov 2009

NeoPharm presents LE-DT Phase I data at the AACR conference

NeoPharm, Inc. today announced the results of a Phase I clinical trial of Liposome Encapsulated Docetaxel (LE-DT) an active component of Taxotere® at a joint International Conference of the American Association for Cancer Research (AACR), the National Cancer Institute (NCI) and the European Organization for Research and Treatment of Cancer (EORTC) being held in Boston, MA.

18 Nov 2009

Five strength training exercises reduce repetitive strain injury caused by office work

Strength training exercises using dumbbells can reduce pain and improve function in the trapezius muscle, the large muscle which extends from the back of the head, down the neck and into the upper back. The exercises also improve the muscle's ability to respond quickly and forcefully among women suffering trapezius myalgia, a tenderness and tightness in the upper trapezius muscle.

18 Nov 2009

First gene expression test for coronary artery disease

The Heart & Vascular Center of Arizona today announced the availability of Corus(TM) CAD, the first and only gene expression test to quantify the likelihood of obstructive(i) coronary artery disease (CAD) in patients with stable chest pain.

18 Nov 2009

Family caregivers can reduce suffering in cancer patients through simple touch and massage techniques

Family caregivers can significantly reduce suffering in cancer patients at home through use of simple touch and massage techniques. These findings were recently reported at the 6th International Conference of the Society for Integrative Oncology.

18 Nov 2009

Phase III randomized clinical trial for Alpharadin to be commenced

International prostate cancer expert Dr. Oliver Sartor of Tulane Cancer Center is the first oncologist in the United States to offer patients an experimental new treatment for late-stage prostate cancer through a multi-center clinical trial that is currently recruiting patients at 100 sites across 20 countries worldwide.

18 Nov 2009

Transplanting people's own stem cells into heart muscle lessens pain and improves ability to walk

The largest national stem cell study for heart disease showed the first evidence that transplanting a potent form of adult stem cells into the heart muscle of subjects with severe angina results in less pain and an improved ability to walk. The transplant subjects also experienced fewer deaths than those who didn't receive stem cells.

18 Nov 2009

FDA approves Qutenza, a pain relief product for patients who suffer from PHN

The Food and Drug Administration (FDA) has approved the approval of Qutenza (capsaicin) 8% patch, a medicated skin patch that relieves the pain of post-herpetic neuralgia (PHN), a serious complication that can occur after a bout with shingles.

18 Nov 2009

Cancer pain drug market to be $3.7 billion in 2018

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, driven by the continued dominance of opioids that include immediate-release morphine and novel fast acting opioid reformulations, the cancer pain drug market will increase from $2.3 billion in 2008 to $3.7 billion in 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

17 Nov 2009

China Sky One Medical reports financial results for third-quarter 2009

China Sky One Medical, Inc., a leading fully integrated pharmaceutical company in the People's Republic of China ("PRC"), today announced record financial results for the third quarter of 2009.

17 Nov 2009

Entellus Medical completes its Series D financing totaling $30MM

Entellus Medical, the Minnesota-based developer of novel, less invasive treatments for chronic conditions of sinusitis, has completed its Series D financing totaling $30MM. The Series D round was led by new investor Essex Woodlands Health Ventures and supported by existing investors Split Rock Partners and SV Life Sciences.

17 Nov 2009

FDA to change its policy regarding the post-harvest processing of raw Gulf Coast oysters

Several weeks ago, the FDA announced its intent to change, by summer 2011, its policy regarding the post-harvest processing of raw Gulf Coast oysters harvested in the warmer months.

17 Nov 2009

Incidence of stroke related to coronary angioplasty remain steady over a 15-year period: Mayo Clinic study

Results of a Mayo Clinic study show the incidence of stroke or mini-stroke related to a coronary angioplasty (http://www.mayoclinic.org/heart-catheterization/types.html) remained steady over a 15-year period. Researchers say this is good news because physicians now are performing the artery-opening procedure on older patients who are sicker and need more complicated treatment.

17 Nov 2009

FDA provides feedback on the pending NDA for EXALGO tablets

CombinatoRx, Incorporated and Neuromed Pharmaceuticals Inc., a privately-held biopharmaceutical company, today announced that on November 13, 2009, representatives of Neuromed discussed the pending New Drug Application (NDA) for the product candidate EXALGOTM (hydromorphone HCl extended release) tablets, seeking FDA approval for the management of moderate to severe pain in opioid tolerant patients requiring continuous, around-the-clock opioid analgesia for an extended period of time, with staff from the United States Food and Drug Administration (FDA).

17 Nov 2009

Pain News and Research

Latest Pain News and Research

Epiphany Biosciences announces results from its valomaciclovir Phase 2b trial for shingles

Recent data from CNSBio's Phase IIa CNSB015 trial to be presented at the Neuropathic Pain conference

Clinical Data commences patient enrollment in Stedivaze Phase III trial

SynCon Chikungunya virus DNA vaccine induces protective neutralizing antibody responses in animal model

New source of information can help prescribers and patients in understanding anticipated side effects of treatments

Pluristem’s PLX-PAD holds promise for critical limb ischemia

Drug interaction between clopidogrel and omeprazole: New safety information

NeoPharm presents LE-DT Phase I data at the AACR conference

Five strength training exercises reduce repetitive strain injury caused by office work

First gene expression test for coronary artery disease

Family caregivers can reduce suffering in cancer patients through simple touch and massage techniques

Phase III randomized clinical trial for Alpharadin to be commenced

Transplanting people's own stem cells into heart muscle lessens pain and improves ability to walk

FDA approves Qutenza, a pain relief product for patients who suffer from PHN

Cancer pain drug market to be $3.7 billion in 2018

China Sky One Medical reports financial results for third-quarter 2009

Entellus Medical completes its Series D financing totaling $30MM

FDA to change its policy regarding the post-harvest processing of raw Gulf Coast oysters

Incidence of stroke related to coronary angioplasty remain steady over a 15-year period: Mayo Clinic study

FDA provides feedback on the pending NDA for EXALGO tablets

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Pain News and Research

Latest Pain News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in